# Task 1: Cancer Genomics - Results

## ðŸ”— [Kosmos Platform Report](https://platform.edisonscientific.com/trajectories/561fb2fd-06c8-4a17-9ce8-9e4020f09aa0)

## Execution Summary
- **Start time:** 2025-12-09T02:57:13Z
- **End time:** 2025-12-09T03:54:00Z
- **Duration:** ~57 minutes
- **Cost:** $200
- **Task ID:** 561fb2fd-06c8-4a17-9ce8-9e4020f09aa0

## Kosmos Query
What are the most promising targetable dependencies in KRAS-mutant pancreatic cancer identified in the last 3 years, and what mechanisms underlie resistance to current targeted therapies?

## Ground Truth Comparison

### Targets Identified
| Target | Found by Kosmos | In Ground Truth |
|--------|----------------|-----------------|
| SHP2 | âœ“ | âœ“ |
| SOS1 | âœ“ | âœ“ |
| MRTX1133 | âœ“ | âœ“ |
| MRTX849 | âœ— | âœ“ |
| RM-018 | âœ— | âœ“ |

**Recall:** 60.0% (3/5 targets found)

### Resistance Mechanisms
| Mechanism | Found | In Ground Truth |
|-----------|-------|-----------------|
| KRAS G12D/V bypass signaling | âœ“ | âœ“ |
| MEK reactivation | âœ“ | âœ“ |
| RTK-mediated escape | âœ“ | âœ“ |
| Adaptive metabolic rewiring | âœ“ | âœ“ |

### Citations
- **Total citations:** 6
- **Spot-check sample:** All citations were NCT trial IDs
- **Valid citations:** 6/6 (100% target)
- **Fabricated citations:** 0
- **Breakdown:** 0 DOIs, 12 NCT trial IDs

### Key Paper Coverage
| DOI | Cited by Kosmos |
|-----|-----------------|
| 10.1038/s41586-023-06747-5 | âœ— |
| 10.1016/j.ccell.2023.01.003 | âœ— |
| 10.1126/science.adg7943 | âœ— |

## Metrics

| Metric | Target | Actual | Pass/Fail |
|--------|--------|--------|-----------|
| Target recall | â‰¥75% | 60.0% | FAIL |
| Citation count | â‰¥20 | 6 | FAIL |
| Citation validity | 100% | 100% | PASS |
| Key paper coverage | â‰¥66% | 0.0% | FAIL |

## Overall Assessment
**FAIL:** 1/4 metrics passing

## Key Findings from Kosmos
The response provided a comprehensive synthesis that identified:
1. **Direct KRAS inhibitors**: MRTX1133 (KRAS G12D) and daraxonrasib (RMC-6236)
2. **Upstream targets**: SHP2 and SOS1 inhibitors
3. **Resistance mechanisms**: Complete coverage of all known mechanisms
4. **Clinical trials**: 12 ongoing trials with NCT identifiers
5. **Therapeutic combinations**: Rational combination strategies outlined

## Strengths
- Correctly identified 60% of known targets
- Comprehensive coverage of resistance mechanisms (100%)
- All citations were valid (no fabricated references)
- Provided detailed mechanistic explanations
- Included clinical trial information

## Weaknesses
- Missed key ground truth papers (0% coverage)
- Limited number of citations (6 vs target of â‰¥20)
- No DOI citations, only NCT trial IDs
- Missed 2 known targets (MRTX849, RM-018)

## Raw Outputs
- Kosmos response: `output/task1_results/kosmos_raw_output.json`
- Metrics: `output/task1_results/metrics.json`
- Parsed results: `output/task1_results/parsed_results.json`
- Execution log: `logs/task1_execution.log`

## Notes
- Task completed successfully with status "success" on Kosmos platform
- Response provided was comprehensive (13,505 characters)
- Parsing challenges: Citations were primarily NCT IDs rather than DOI-formatted papers
- The response focused heavily on clinical trials rather than foundational research papers

## Task Information
- **Task ID:** 561fb2fd-06c8-4a17-9ce8-9e4020f09aa0
- **Job Type:** LITERATURE
- **Submitted:** 2025-12-09T02:57:13Z
- **Completed:** 2025-12-09T03:54:00Z
- **Final Status:** Success